San Francisco, CA, United States of America

Bruce Scharschmidt

USPTO Granted Patents = 19 

 

Average Co-Inventor Count = 1.9

ph-index = 9

Forward Citations = 168(Granted Patents)


Location History:

  • South San Francisco, CA (US) (2014)
  • San Francisco, CA (US) (2013 - 2020)

Company Filing History:


Years Active: 2013-2020

Loading Chart...
Loading Chart...
19 patents (USPTO):Explore Patents

Title: Bruce Scharschmidt: Innovator in Urea Cycle Disorder Treatment

Introduction

Bruce Scharschmidt, based in San Francisco, CA, is a notable inventor with an impressive portfolio of 19 patents. His innovative work primarily focuses on the treatment of urea cycle disorders in neonates and infants, showcasing a commitment to enhancing pediatric healthcare through medicinal advancements.

Latest Patents

Among his latest patents, Scharschmidt has contributed significantly to the field with two notable disclosures. The first relates to the treatment of urea cycle disorders in infants, employing nitrogen scavenging drugs such as glycerol phenylbutyrate. This patent emphasizes the importance of adjusting drug dosages based on various biomarkers, specifically urinary-PAGN and the plasma PAA:PAGN ratio, ensuring safe administration to vulnerable populations. The second patent outlines methods of therapeutic monitoring for nitrogen scavenging drugs, providing innovative ways to evaluate daily ammonia exposure. By utilizing a singular fasting ammonia blood level measurement, these methods facilitate accurate dosage adjustments and healthy management of nitrogen retention disorders.

Career Highlights

Throughout his career, Bruce Scharschmidt has made impactful strides in the biotechnology industry. He has worked with notable companies such as Horizon Therapeutics and Hyperion Therapeutics, where his contributions have been instrumental in developing treatments for challenging medical conditions.

Collaborations

During his career, Scharschmidt has collaborated with esteemed professionals in the field. One such notable coworker is Masoud Mokhtarani, with whom he has worked to push the boundaries of research and innovation in the treatment of urea cycle disorders.

Conclusion

In conclusion, Bruce Scharschmidt's ongoing commitment to innovation in healthcare, particularly in treating urea cycle disorders in infants, continues to make a profound difference in the lives of patients and their families. His extensive patent portfolio and collaborative efforts with industry leaders underscore his significance as an inventor in the biotechnology sector.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…